CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Large B-cell Lymphoma
Interventions
BIOLOGICAL

CNCT19

2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion

DRUG

Gemcitabine Injection

600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,

DRUG

busulfan

105mg/m2, day -7 until -5,

DRUG

Melphalan Injection

60mg/m2, day -3, -2

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER